Drug Profile
Research programme: cholecystokinin receptor modulators - Johnson & Johnson
Alternative Names: CCK-1 receptor antagonists - Johnson & Johnson; CCK-2 receptor modulators - Johnson & Johnson; CCK-2/gastrin receptor antagonists - Johnson & Johnson; CCK-B receptor antagonists - Johnson & Johnson; CCK-B receptor modulators - Johnson & Johnson; JNJ-26070109; Oral CCK-2 antagonists - Johnson & Johnson Pharmaceutical Research & Development LLCLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Research & Development
- Class Small molecules
- Mechanism of Action Cholecystokinin A receptor antagonists; Cholecystokinin B receptor antagonists; Cholecystokinin B receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gastro-oesophageal reflux; Gastrointestinal disorders; Pancreatitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Gastro-oesophageal-reflux in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pancreatitis in USA